Researcher
Mazzone Max
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Max Mazzone (KU Leuven)
Affiliations
- Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Mazzone Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → 30 Sep 2022
Projects
1 - 8 of 8
- Targeting eicosanoid metabolism to overcome tumor immunosuppressionFrom1 Feb 2024 → TodayFunding: HORIZON.1.1 - European Research Council (ERC)
- Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapyFrom1 Sep 2022 → 29 Feb 2024Funding: HORIZON.1.1 - European Research Council (ERC)
- GLUDI as a potential target in Muscular DystrophyFrom1 Aug 2022 → 31 Mar 2024Funding: Other international institutions, not mentioned elsewhere
- VIB Grant for Mazzone Lab_Period:2022-01-01-2026-12-31From1 Jan 2022 → TodayFunding: FRI - Project driven research
- Harnessing tumor metabolism to overcome immunosupression — ImmunoFitFrom1 Jul 2018 → 30 Jun 2023Funding: HORIZON.1.1 - European Research Council (ERC)
- Targeting the metabolism-immune system connections in cancer - META-CAN - Marie Sklodowska-Curie actions (ITN)From1 Sep 2017 → 31 Aug 2021Funding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- A comparative clinical study of a stool-based versus a blood based screening test for early detection of CRC - Monomark - ERC POCFrom1 Apr 2017 → 30 Sep 2018Funding: HORIZON.1.1 - European Research Council (ERC)
- VIB Grant for Mazzone Lab_Period:2017-01-01-2021-12-31From1 Jan 2017 → 31 Dec 2021Funding: FRI - Project driven research
Publications
1 - 10 of 89
- From monocyte-derived macrophages to resident macrophages-how metabolism leads their way in cancer.(2024)
Authors: Andreia Raquel Pereira Nunes, Marcello Delfini, Massimiliano Mazzone
Pages: e-pub - PHD2 Constrains Antitumor CD8+ T-cell Activity.(2023)
Authors: Massimiliano Mazzone
Pages: 339-350 - The pulmonary vasculature in lethal COVID-19 and idiopathic pulmonary fibrosis at single-cell resolution.(2023)
Authors: Laura de Rooij, Lisa Becker, Laure-Anne Teuwen, Bram Boeckx, Subramanian Abhishek x, Sébastien Dumas, Elda Meta, Mila Borri, Liliana Sokol, Anh Co Khanh Truong, et al.
Pages: 520-535 - A collaborative synthetase.(2023)
Authors: Massimiliano Mazzone
Pages: 255-256 - A Metabolic Gene Survey Pinpoints Fucosylation as a Key Pathway Underlying the Suppressive Function of Regulatory T Cells in Cancer.(2023)
Authors: Sotiria Pinioti, Himal Sharma, Nina Flerin, Elien De Bousser, Nico Callewaert, Mario di Matteo, Massimiliano Mazzone
Pages: 1611-1629 - Stroma-derived miR-214 coordinates tumor dissemination.(2023)
Authors: Federico Virga, Massimiliano Mazzone
Pages: 20 - Immunoediting instructs tumor metabolic reprogramming to support immune evasion.(2023)
Authors: Mario di Matteo, Massimiliano Mazzone
Pages: 118-133.e7 - Candida albicans stimulates formation of a multi-receptor complex that mediates epithelial cell invasion during oropharyngeal infection.(2023)
Authors: Massimiliano Mazzone
Pages: e1011579 - Mitochondria metabolism sets the species-specific tempo of neuronal development.(2023)
Authors: Ryohei Iwata, Pierre Casimir, Emir Erkol, Leila Boubakar, Isabel Maria Gallego Lopez, Anke Vandekeere, Nikky Corthout, Massimiliano Mazzone, Stein Aerts, Bart Ghesquière, et al.
Pages: eabn4705 - A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-?B signaling.(2023)
Authors: Patricia Altea Manzano, Ginevra Doglioni, Alejandro Cuadros, Juan Fernandez Garcia, Qi Wu, Xiaozheng Liu, Oskar Marin Bejar, Sofie Demeyer, Margherita Demicco, Hamza Furkan Alkan, et al.
Pages: 344-364
Patents
1 - 10 of 10
- INHIBITION OF SLC4A4 IN THE TREATMENT OF CANCER (Inventor)
- Combination of P2Y6 inhibitors and immune checkpoint inhibitors (Inventor)
- Combination of P2Y6 inhibitors and immune checkpoint inhibitors (Inventor)
- INHIBITION OF SLC4A4 IN THE TREATMENT OF CANCER (Inventor)
- CD8+ T-CELLS LACKING PLEXINS AND THEIR APPLICATION IN CANCER TREATMENT (Inventor)
- Cancer treatment by targeting Plexins in the immune compartment (Inventor)
- Cancer treatment by targeting Plexins in the immune compartment (Inventor)
- CD8+ T-CELLS LACKING PLEXINS AND THEIR APPLICATION IN CANCER TREATMENT (Inventor)
- Combination of P2Y6 inhibitors and immune checkpoint inhibitors (Inventor)
- Biomarker for anti-tumor therapy (Inventor)